Quantcast
Last updated on April 21, 2014 at 4:51 EDT

Latest Reperfusion injury Stories

2014-01-06 10:19:45

Currently intraoperative monitoring using somatosensory evoked potentials has been widely recognized to prevent iatrogenic spinal cord injury. Previous studies only reported the monitoring effects of somatosensory evoked potentials after mechanical factors-caused spinal cord injury. However, spinal cord injury is not only triggered by mechanical factors, biochemical factors and vascular factors may cause spinal cord ischemia-reperfusion injury. It remains unclear whether spinal cord...

2013-03-22 08:24:26

LUND, Sweden, March 22, 2013 /PRNewswire/ -- NeuroVive, a leading mitochondrial medicine company, announces that the 600th patient has been recruited to a pivotal Phase III European, multi-center trial (CIRCUS trial) assessing CicloMulsion(R) (a special formulation of cyclosporine for acute cardiac injuries) for the treatment of heart reperfusion injury following stenting in patients with myocardial infarction. The CIRCUS trial (does Cyclosporine ImpRove Clinical oUtcome...

2013-03-19 14:20:06

Potential approach to treating atherosclerosis and other chronic inflammatory diseases A multicenter team of researchers, including scientists at Columbia University Medical Center (CUMC), Brigham and Women's Hospital (BWH), Mount Sinai School of Medicine, and Massachusetts Institute of Technology, has developed biodegradable nanoparticles that are capable of delivering inflammation-resolving drugs to sites of tissue injury. The nanoparticles, which were successfully tested in mice, have...

2013-02-01 08:25:12

LUND, Sweden, February 1, 2013 /PRNewswire/ -- NeuroVive, a leading mitochondrial medicine company, is pleased to announce the appointment of Jan Nilsson as Chief Operating Officer (COO). Jan will oversee the day-to-day operations of the Company and support the planned commercialisation of CicloMulsion(R) and NeuroSTAT(R), NeuroVive's leading products for the treatment of acute cardiovascular and neurological conditions through mitochondrial protection. Jan has over 30...

2012-11-23 08:21:08

SUNNYVALE, Calif. and NEW YORK, Nov. 23, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that OneMedPlace's Research Division has released an update to its previous research report on Amarantus Biosciences, highlighting recently announced positive ischemic heart disease...

2012-08-28 02:29:30

BOULDER, Colo., Aug. 28, 2012 /PRNewswire/ -- Bolder BioTechnology, Inc. announced today publication of preclinical research demonstrating utility of interleukin-11 (IL-11) and the company's long-acting IL-11 analog to prevent kidney damage from ischemia reperfusion injury in mice. This work may lead to new therapeutic approaches to prevent acute kidney injury and ischemia reperfusion injury to multiple organ types. The studies were performed in the laboratory of H. Thomas Lee, M.D.,...

2012-02-01 14:32:19

Source of damage to donor organs identified For patients with incurable pulmonary conditions, a lung transplantation is the only available treatment option. However, suitable donor organs are scarce, and even getting them to prospective recipients is not easy. As Professor Alexander Dietrich of the Walther Straub Institute of Pharmacology and Toxicology at LMU explains, “An isolated lung which is no longer perfused with blood can become so severely damaged that it is no longer...

2011-08-05 22:40:18

FINDINGS: A man-made fat called Intralipid, which is currently used as a component of intravenous nutrition and to treat rare overdoses of local anesthetics, may also offer protection for patients suffering from heart attacks. Current treatment for a heart attack focuses on limiting the duration of the ischemic period, when blood flow to tissues is reduced, and on subsequently opening arteries to reestablish normal coronary blood flow. It is well known that injury to the heart muscle can...

2011-04-19 06:00:00

SEATTLE, April 19, 2011 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that research on mannan-binding lectin-associated serine protease-2 (MASP-2) has been published in the April 18, 2011 Early Online Edition of the Proceedings of the National Academy of Sciences (PNAS). Wilhelm Schwaeble, Ph.D., Professor of Immunology at the University of Leicester and the senior author of the paper, led an international team of researchers who demonstrated that blocking MASP-2...

2010-11-16 19:17:09

University of Cincinnati researchers have discovered a new protein that could be cardioprotective during heart attack, potentially leading to more targeted treatments for patients at risk. These findings are being presented at the American Heart Association's (AHA) Scientific Sessions in Chicago Nov. 16. Researchers in the department of pharmacology and cell biophysics, led by Wen Zhao, PhD, and Chi Keung Lam, a PhD student, under the direction of Litsa Kranias, PhD, AHA distinguished...